Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 138 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016', provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted pipeline therapeutics. 

The report provides comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- The report reviews Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Overview 10
Therapeutics Development 11
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Stage of Development 11
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Therapy Area 12
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Indication 13
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Companies 17
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Products under Development by Universities/Institutes 24
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Therapeutics Assessment 26
Assessment by Monotherapy/Combination Products 26
Assessment by Mechanism of Action 27
Assessment by Route of Administration 28
Assessment by Molecule Type 29
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Companies Involved in Therapeutics Development 31
AbbVie Inc. 31
Advinus Therapeutics Ltd 33
ArQule, Inc. 34
BeiGene, Ltd. 35
Bristol-Myers Squibb Company 36
Celgene Corporation 37
CrystalGenomics, Inc. 38
Genentech, Inc. 39
Hanmi Pharmaceuticals, Co. Ltd. 40
LSK BioPartners, Inc. 41
Merck KGaA 42
Ono Pharmaceutical Co., Ltd. 43
Pharmacyclics, Inc. 44
Principia Biopharma Inc. 45
Redx Pharma Plc 46
Simcere Pharmaceutical Group 47
Sunesis Pharmaceuticals, Inc. 48
Takeda Pharmaceutical Company Limited 49
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Drug Profiles 50
acalabrutinib - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
ARQ-531 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
BGB-3111 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
CG-026806 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
CG-036806 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Drug to Inhibit BTK for Undisclosed Indications - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
EBI-1266 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
EBI-1367 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
HCI-1401 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
HCI-1684 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
HM-71224 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
ibrutinib - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
M-2951 - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
M-7583 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
ONO-4059 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
PLS-123 - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
PNQ-154 - Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
PNQ-849 - Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
PRN-1008 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
PRN-473 - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
RDX-002 - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
RG-7845 - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Small Molecule to Inhibit Bruton Tyrosine Kinase for Inflammation - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Small Molecule to Inhibit BTK for Immunology - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
Small Molecule to Inhibit BTK for Oncology - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
Small Molecules to Inhibit BTK for Oncology - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
Small Molecules to Inhibit BTK for Rheumatoid Arthritis - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
SNS-062 - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
spebrutinib besylate - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
TAK-020 - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
X-022 - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Dormant Projects 117
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Discontinued Products 120
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Featured News & Press Releases 121
Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting 121
Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund 123
May 31, 2016: Janssen's IMBRUVICA (ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia 124
May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead 125
May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 2016 125
May 18, 2016: Janssen to Present Data on Ibrutinib at the 2016 American Society of Clinical Oncology Annual Meeting 126
May 12, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstroms Macroglobulinemia 127
May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients 128
Apr 29, 2016: European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients 130
Apr 29, 2016: Janssen's IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients 131
Mar 23, 2016: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 132
Mar 14, 2016: Diplomat Now Dispensing IMBRUVICA as First-Line Therapy for Chronic Lymphocytic Leukemia 132
Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111 133
Mar 04, 2016: U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia 133
Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications 135
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Development by Companies, H1 2016 (Contd..2) 20
Products under Development by Companies, H1 2016 (Contd..3) 21
Products under Development by Companies, H1 2016 (Contd..4) 22
Products under Development by Companies, H1 2016 (Contd..5) 23
Number of Products under Investigation by Universities/Institutes, H1 2016 24
Products under Investigation by Universities/Institutes, H1 2016 25
Assessment by Monotherapy/Combination Products, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 27
Number of Products by Stage and Route of Administration, H1 2016 28
Number of Products by Stage and Molecule Type, H1 2016 30
Pipeline by AbbVie Inc., H1 2016 31
Pipeline by Advinus Therapeutics Ltd, H1 2016 33
Pipeline by ArQule, Inc., H1 2016 34
Pipeline by BeiGene, Ltd., H1 2016 35
Pipeline by Bristol-Myers Squibb Company, H1 2016 36
Pipeline by Celgene Corporation, H1 2016 37
Pipeline by CrystalGenomics, Inc., H1 2016 38
Pipeline by Genentech, Inc., H1 2016 39
Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 40
Pipeline by LSK BioPartners, Inc., H1 2016 41
Pipeline by Merck KGaA, H1 2016 42
Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 43
Pipeline by Pharmacyclics, Inc., H1 2016 44
Pipeline by Principia Biopharma Inc., H1 2016 45
Pipeline by Redx Pharma Plc, H1 2016 46
Pipeline by Simcere Pharmaceutical Group, H1 2016 47
Pipeline by Sunesis Pharmaceuticals, Inc., H1 2016 48
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 49
Dormant Projects, H1 2016 117
Dormant Projects (Contd..1), H1 2016 118
Dormant Projects (Contd..2), H1 2016 119
Discontinued Products, H1 2016 120